

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PATI882295

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Amended and Restated Intellectual Property Security Agreement
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SOLENO THERAPEUTICS, INC.	03/12/2025
ESSENTIALIS, INC.	03/12/2025
<b>RECEIVING PARTY DATA</b>	
<b>Company Name:</b>	Oxford Finance LLC, as Collateral Agent
<b>Street Address:</b>	115 South Union St, Suite 300
<b>City:</b>	Alexandria
<b>State/Country:</b>	VIRGINIA
<b>Postal Code:</b>	22314
<b>PROPERTY NUMBERS Total: 16</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	15671792
Application Number:	15195826
Application Number:	16041237
Application Number:	16573965
Application Number:	16680093
Application Number:	17332878
Application Number:	12391990
Application Number:	11614044
Application Number:	13846542
Application Number:	14940018
Application Number:	14466852
Application Number:	14458032
Application Number:	18421914
Application Number:	18454595
Application Number:	18824811
Application Number:	18988636
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent</i>	
<b>PATENT</b>	

***using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***

**Phone:** 2025218721  
**Email:** IpTeam@CogencyGlobal.Com  
**Correspondent Name:** Troy Jones  
**Address Line 1:** 1025 Connecticut Ave NW, Suite 712  
**Address Line 4:** Washington, DISTRICT OF COLUMBIA 20036

<b>ATTORNEY DOCKET NUMBER:</b>	2691020 TJ
--------------------------------	------------

<b>NAME OF SUBMITTER:</b>	Troy Jones
---------------------------	------------

<b>SIGNATURE:</b>	/Troy Jones/
-------------------	--------------

<b>DATE SIGNED:</b>	03/12/2025
---------------------	------------

**Total Attachments: 8**

source=EXECUTED.Oxford - Soleno - A&R Intellectual Property Security Agreement (03.2025)#page1.tiff  
source=EXECUTED.Oxford - Soleno - A&R Intellectual Property Security Agreement (03.2025)#page2.tiff  
source=EXECUTED.Oxford - Soleno - A&R Intellectual Property Security Agreement (03.2025)#page3.tiff  
source=EXECUTED.Oxford - Soleno - A&R Intellectual Property Security Agreement (03.2025)#page4.tiff  
source=EXECUTED.Oxford - Soleno - A&R Intellectual Property Security Agreement (03.2025)#page5.tiff  
source=EXECUTED.Oxford - Soleno - A&R Intellectual Property Security Agreement (03.2025)#page6.tiff  
source=EXECUTED.Oxford - Soleno - A&R Intellectual Property Security Agreement (03.2025)#page7.tiff  
source=EXECUTED.Oxford - Soleno - A&R Intellectual Property Security Agreement (03.2025)#page8.tiff

## AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT

March 12, 2025

This Amended and Restated Intellectual Property Security Agreement (this “**Agreement**”) is entered into as of the date first written above, by and among OXFORD FINANCE LLC, a Delaware limited liability company, as collateral agent for the Lenders (as defined below) (in such capacity, the “**Collateral Agent**”), and SOLENO THERAPEUTICS, INC., a Delaware corporation, and ESSENTIALIS, INC., a Delaware corporation (collectively, “**Grantor**”) and amends and restates in its entirety that certain Intellectual Property Security Agreement dated as of December 17, 2024 by and among Collateral Agent and Grantor.

### RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the “**Loans**”) in the amounts and manner set forth in that certain Loan and Security Agreement dated as of the date hereof by and among Collateral Agent, the lenders listed on Schedule 1.1 thereof or otherwise party thereto from time to time (collectively, the “**Lenders**”), and Grantor, individually and collectively, jointly and severally, as Borrower (as the same may be further amended, modified or supplemented from time to time, the “**Loan Agreement**”; capitalized terms used but not defined herein have the meanings ascribed thereto in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents and Mask Works to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral (subject to the exclusions set forth in the Loan Agreement).

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its Intellectual Property constituting Collateral (including without limitation those Copyrights, Patents and Trademarks listed on **Exhibits A, B and C** hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof. Grantor hereby confirms that the attached schedules of such Grantor’s Copyright, Patent and Trademark applications and registrations, which are registered or filed with the United States Patent and Trademark Office or the United States Copyright Office, as applicable, attached hereto as **Exhibits A, B and C**, respectively, are complete and accurate as of the date hereof.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

Each Grantor hereby authorizes Collateral Agent to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property which such Grantor obtains subsequent to the date of

this Agreement, and (b) file a duplicate of this Agreement containing amended exhibits reflecting such new Intellectual Property with the United States Patent and Trademark Office or the United States Copyright Office, as applicable

*[Balance of Page Intentionally Left Blank]*


IN WITNESS WHEREOF, the parties have caused this Amended and Restated Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

Address of Grantor:


100 Marine Parkway, Suite 400  
Redwood City, CA 94065  
Attn: General Counsel  
Email: legal@solenolife

**GRANTOR:**

SOLENO THERAPEUTICS, INC.

Signed by:  
  
By: \_\_\_\_\_  
Name: James Mackaness  
Title: Chief Financial Officer

ESSENTIALIS, INC.

Signed by:  
  
By: \_\_\_\_\_  
Name: James Mackaness  
Title: Chief Financial Officer

Address of Collateral Agent:

115 South Union Street, Suite 300  
Alexandria, Virginia 22314  
Attn: Legal Department  
Email: legaldepartment@oxfordfinance.com

**COLLATERAL AGENT:**

OXFORD FINANCE LLC

By: \_\_\_\_\_  
Name: Colette H. Featherly  
Title: Senior Vice President

*[Signature Page to A&R Intellectual Property Security Agreement]*

**PATENT**  
**REEL: 070494 FRAME: 0046**

IN WITNESS WHEREOF, the parties have caused this Amended and Restated Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

**GRANTOR:**

Address of Grantor:

100 Marine Parkway, Suite 400  
Redwood City, CA 94065  
Attn: General Counsel  
Email: legal@solenolife

SOLENO THERAPEUTICS, INC.

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

ESSENTIALIS, INC.


By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

Address of Collateral Agent:

115 South Union Street, Suite 300  
Alexandria, Virginia 22314  
Attn: Legal Department  
Email: legaldepartment@oxfordfinance.com

**COLLATERAL AGENT:**

OXFORD FINANCE LLC

By:  \_\_\_\_\_  
Name: Colette H. Featherly  
Title: Senior Vice President

**Exhibit A**

**Copyrights**

None.

**Exhibit B****Patents**

<b><u>Grantor</u></b>	<b><u>Country</u></b>	<b><u>Publication Number</u></b>	<b><u>Title</u></b>	<b><u>Application Number</u></b>	<b><u>Application Date</u></b>
ESSENTIALIS, INC.	UNITED STATES	20180021344	METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME	15671792	8-8-2017
ESSENTIALIS, INC.	UNITED STATES	20170143732	SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF	15195826	6-28-2016
ESSENTIALIS, INC.	UNITED STATES	20190105327	METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME	16041237	7-20-2018
ESSENTIALIS, INC.	UNITED STATES	20200147100	METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME	16573965	9-17-2019
ESSENTIALIS, INC.	UNITED STATES	20200222417	SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF	16680093	11-11-2019
ESSENTIALIS, INC.	UNITED STATES	20220047605	SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF	17332878	5-27-2021
ESSENTIALIS, INC.	UNITED STATES	20090148526	SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF	12391990	2-24-2009
ESSENTIALIS, INC.	UNITED STATES	20070191351	SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF	11614044	12-20-2006
ESSENTIALIS, INC.	UNITED STATES	20130225806	SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF	13846542	3-18-2013
ESSENTIALIS, INC.	UNITED STATES	20160136178	METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME	14940018	11-12-2015
ESSENTIALIS, INC.	UNITED STATES	20140364425	SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF	14466852	8-22-2014
ESSENTIALIS, INC.	UNITED STATES	20140350001	PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF	14458032	8-12-2014
ESSENTIALIS, INC.	UNITED STATES	20240207284	METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME	18421914	1-24-2024
ESSENTIALIS, INC.	UNITED STATES	20240252507	SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF	18454595	8-23-2023
ESSENTIALIS, INC.	UNITED STATES	20240423996	(Track One) METHODS FOR TREATING SUBJECTS WITH	18824811	9-4-2024



<u>Grantor</u>	<u>Country</u>	<u>Publication Number</u>	<u>Title</u>	<u>Application Number</u>	<u>Application Date</u>
			PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME		
ESSENTIALIS, INC.	UNITED STATES	Pending	(Track One) METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME	18988636	12-19-2024

**Exhibit C**

**Trademarks**

<b><u>Owner</u></b>	<b><u>Country</u></b>	<b><u>Mark Description</u></b>	<b><u>Serial/Registration No.</u></b>	<b><u>File Date</u></b>
Soleno Therapeutics, Inc. (CORPORATION; Delaware, USA)	UNITED STATES	SOLENO ONE	98863148	11-20-2024
Soleno Therapeutics, Inc. (CORPORATION; DELAWARE, USA)	UNITED STATES	SOLENO	90238786	10-06-2020
Soleno Therapeutics, Inc. (CORPORATION; DELAWARE, USA)	UNITED STATES	IMBEVLI	90744615	5-31-2021
Soleno Therapeutics, Inc. (CORPORATION; Delaware, USA)	UNITED STATES	KABREY	98503089	4-16-2024
Soleno Therapeutics, Inc. (CORPORATION; Delaware, USA)	UNITED STATES	VYKAT	98844270	11-08-2024
Soleno Therapeutics, Inc. (CORPORATION; Delaware, USA)	UNITED STATES	KYDECCRU	98867294	11-22-2024